Finnish “nanoparticle medicine enabling company” Nanoform has announced the appointment of former Catalent executive Sally Langa as Head of US Sales. Langa was most recently VP, Global Business Development, Development and Analytical Services at Catalent Pharma Solutions and has previously held business development/sales positions at Halo Pharmaceutical and Patheon.
The company, which announced in December 2019 that it had applied for GMP certification for its new facility in Helsinki, Finland, was the winner of the 2019 Excellence in Pharma: Formulation award at CPhI
Nanoform CEO Edward Hæggström commented, “I am delighted to welcome Sally Langa to Nanoform. The US market is the largest in the world, and with this key appointment, we are now well positioned to build upon our current traction in this region.”
Chief Commercial Officer Christian Jones added, “It is fantastic to have Sally join the commercial team. We have seen strong interest from the US market and this appointment is key in driving further growth and ensuring our technology is as widely adopted as possible by our current and future partners. I look forward to working with a fellow professional with exceptional expertise in business development and in-depth knowledge of formulation enhancement.”
Langa said, “I am thrilled to have the opportunity to work with Nanoform to strengthen its presence in the US, particularly at such a pivotal time in its growth trajectory. It is a privilege to be a part of the development of life-changing technology, and to work within a team of similarly driven professionals. Nanoform’s technology is unique and powerful and will address so many challenges faced by US Pharma and Biotech. It will be a great pleasure to enable our new partners to overcome their solubility and bioavailability challenges, and to help them succeed in their key drug developments.”
Read the Nanoform press release.
